Gastrointestinal Cancer News

President Joe Biden plans to nominate NCI Director Monica M. Bertagnolli, MD, FACS, FASCO, to serve as director of the NIH, according to published reports.

Whole-exome sequencing identified carriers of predisposition genes for hereditary breast and ovarian cancer or Lynch syndrome who, under current guidelines, would not have qualified for genetic testing, according to study results.

Cancer Moonshot’s goal of reducing the cancer death rate by at least 50% over the next 25 years will depend upon greater access to and utilization of cancer prevention interventions, according to a study presented at an NCI press briefing.

The addition of panitumumab vs. bevacizumab to standard first-line chemotherapy significantly extended OS for certain patients with RAS wild-type metastatic colorectal cancer, according to data published in JAMA.

The addition of pembrolizumab to gemcitabine and cisplatin conferred a statistically significant and clinically meaningful survival benefit for patients with advanced biliary tract cancer, according to results of the KEYNOTE-966 study.

Individuals of African ancestry treated for colorectal cancer had fewer actionable genetic alterations than those of European ancestry, making them less likely to be eligible for immunotherapy, study results showed.

Cardiovascular disease, especially atherosclerotic CVD, was associated with increased risk for cancer diagnosis, according to a study published in JACC: CardioOncology.

Adjuvant treatment with atezolizumab and bevacizumab extended RFS compared with active surveillance among patients with hepatocellular carcinoma, according to study findings presented at AACR Annual Meeting.

The FDA announced several regulatory actions the past few weeks.

Patients with rectal cancer who were observed by a watch-and-wait approach reported “good” quality of life and less major bowel dysfunction than those requiring surgery, according to study results in JAMA Surgery.